JP2023549555A5 - - Google Patents
Info
- Publication number
- JP2023549555A5 JP2023549555A5 JP2023529918A JP2023529918A JP2023549555A5 JP 2023549555 A5 JP2023549555 A5 JP 2023549555A5 JP 2023529918 A JP2023529918 A JP 2023529918A JP 2023529918 A JP2023529918 A JP 2023529918A JP 2023549555 A5 JP2023549555 A5 JP 2023549555A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- sequence
- seq
- isolated antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115272P | 2020-11-18 | 2020-11-18 | |
| US63/115,272 | 2020-11-18 | ||
| US202163244662P | 2021-09-15 | 2021-09-15 | |
| US63/244,662 | 2021-09-15 | ||
| PCT/US2021/059955 WO2022109178A1 (en) | 2020-11-18 | 2021-11-18 | Anti-marco antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549555A JP2023549555A (ja) | 2023-11-27 |
| JP2023549555A5 true JP2023549555A5 (https=) | 2024-11-20 |
Family
ID=81588283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023529918A Pending JP2023549555A (ja) | 2020-11-18 | 2021-11-18 | 抗ｍａｒｃｏ抗体及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11572407B2 (https=) |
| EP (1) | EP4247419A4 (https=) |
| JP (1) | JP2023549555A (https=) |
| KR (1) | KR20230121759A (https=) |
| AU (1) | AU2021382658A1 (https=) |
| CA (1) | CA3198579A1 (https=) |
| IL (1) | IL302874A (https=) |
| MX (1) | MX2023005841A (https=) |
| TW (1) | TW202237648A (https=) |
| WO (1) | WO2022109178A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11572407B2 (en) | 2020-11-18 | 2023-02-07 | Pionyr Immunotherapeutics, Inc. | Anti-MARCO antibodies and uses thereof |
| CA3238769A1 (en) * | 2021-11-23 | 2023-06-01 | William Brondyk | Anti-ngf antibodies and uses thereof |
| WO2024059256A1 (en) * | 2022-09-15 | 2024-03-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer |
| WO2024081807A2 (en) * | 2022-10-12 | 2024-04-18 | Massachusetts Institute Of Technology | Library-scale methods for polypeptide functional analysis |
| WO2025102054A1 (en) * | 2023-11-09 | 2025-05-15 | Massachusetts Institute Of Technology | Methods of screening for secreted functional molecules |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916766A (en) | 1996-05-23 | 1999-06-29 | Smithkline Beecham Corporation | Human marco scavenger receptor |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| JP2010534335A (ja) * | 2007-07-24 | 2010-11-04 | アイエスエス イミューン システム スティミュレーション アーベー | 全身性エリテマトーデス感受性を予測するための方法及び手段 |
| WO2009114547A2 (en) | 2008-03-10 | 2009-09-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced dendritic cells for cancer immunotherapy |
| KR20130108295A (ko) * | 2010-08-13 | 2013-10-02 | 베일러 리서치 인스티튜트 | 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 |
| TW201247706A (en) * | 2011-03-08 | 2012-12-01 | Baylor Res Inst | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| EP3302558A4 (en) | 2015-06-01 | 2019-01-16 | The Rockefeller University | ANTI-TUMOR MEDIUM AND METHOD OF USE |
| WO2017062363A1 (en) | 2015-10-05 | 2017-04-13 | Joslin Diabetes Center | Methods of use of betatrophin |
| US20190336615A1 (en) | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CN110709422B (zh) | 2017-04-19 | 2023-12-26 | 马伦戈治疗公司 | 多特异性分子及其用途 |
| TWI828625B (zh) | 2017-06-25 | 2024-01-11 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質以及彼之製造及使用方法 |
| EP3668899A4 (en) | 2017-08-18 | 2020-09-02 | Celdara Medical, LLC | CELL-BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE DISEASES |
| WO2019068007A1 (en) | 2017-09-28 | 2019-04-04 | Immpact-Bio Ltd. | UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR) |
| US20210000920A1 (en) | 2017-12-22 | 2021-01-07 | Atossa Therapeutics, Inc. | Intraductal methods of treatment of breast disorders |
| AU2019228381B2 (en) | 2018-02-28 | 2021-12-16 | Pfizer Inc. | IL-15 variants and uses thereof |
| BR112021006100A2 (pt) | 2018-09-28 | 2021-07-20 | Immpact-Bio Ltd. | métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer |
| AU2019394364A1 (en) * | 2018-12-05 | 2021-06-17 | The Council Of The Queensland Institute Of Medical Research | Rank antagonists and uses therefor |
| EP3906055A4 (en) | 2019-01-04 | 2023-01-04 | Trio Pharmaceuticals, Inc. | MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES |
| JP2022519378A (ja) | 2019-02-08 | 2022-03-23 | グッド ティー セルズ、 インコーポレイテッド | がん治療のためのｔ細胞の活性化方法 |
| US20220152148A1 (en) | 2019-03-18 | 2022-05-19 | The Broad Institute, Inc. | Modulation of type 2 immunity by targeting clec-2 signaling |
| JP2022536598A (ja) | 2019-05-07 | 2022-08-18 | イミューニコム， インコーポレイテッド | 体外アフェレーシスによるチェックポイント阻害剤に対する応答の上昇 |
| JP2022536684A (ja) | 2019-06-11 | 2022-08-18 | マイエロイド・セラピューティクス，インコーポレーテッド | マクロファージ特異的エンゲージャー組成物およびその使用方法 |
| EP4003994A4 (en) | 2019-07-31 | 2023-09-13 | Oncour Pharma, Inc. | TREATMENT OF EVASIVE IMMUNE TUMORS |
| US11572407B2 (en) | 2020-11-18 | 2023-02-07 | Pionyr Immunotherapeutics, Inc. | Anti-MARCO antibodies and uses thereof |
-
2021
- 2021-11-18 US US17/529,927 patent/US11572407B2/en active Active
- 2021-11-18 JP JP2023529918A patent/JP2023549555A/ja active Pending
- 2021-11-18 KR KR1020237020512A patent/KR20230121759A/ko active Pending
- 2021-11-18 IL IL302874A patent/IL302874A/en unknown
- 2021-11-18 MX MX2023005841A patent/MX2023005841A/es unknown
- 2021-11-18 CA CA3198579A patent/CA3198579A1/en active Pending
- 2021-11-18 WO PCT/US2021/059955 patent/WO2022109178A1/en not_active Ceased
- 2021-11-18 AU AU2021382658A patent/AU2021382658A1/en active Pending
- 2021-11-18 TW TW110143070A patent/TW202237648A/zh unknown
- 2021-11-18 EP EP21895613.4A patent/EP4247419A4/en active Pending
-
2022
- 2022-12-19 US US18/068,237 patent/US12378311B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023549555A5 (https=) | ||
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| JP2021506244A5 (https=) | ||
| CN110431231B (zh) | 抗-cd3抗体和包含所述抗体的分子 | |
| JP2022514734A5 (https=) | ||
| JP7649744B2 (ja) | Ｂｔｎ３ａ結合タンパク質及びその使用 | |
| JP2021508469A5 (https=) | ||
| JP2024056687A5 (https=) | ||
| TW201833141A (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| RU2017122014A (ru) | Антитела к c10orf54 и их применения | |
| JP2021520832A5 (https=) | ||
| JP2024001073A5 (https=) | ||
| WO2022002033A1 (zh) | 具有H2L2与HCAb结构的结合蛋白 | |
| JP2025501206A (ja) | Ｇｐｒｃ５ｄ抗体及びその応用 | |
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| JP2022540610A5 (https=) | ||
| KR20220030934A (ko) | 항-gal9 면역-억제 결합 분자 | |
| JP2023547662A5 (https=) | ||
| RU2010122044A (ru) | УЛУЧШЕННЫЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Nogo-А И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ | |
| CA3160765A1 (en) | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof | |
| JP2022523145A5 (https=) | ||
| WO2023125289A1 (zh) | 抗pd-1抗体及其用途 | |
| JP2025509702A (ja) | ＧＰＣ３陽性悪性細胞を標的殺傷するための二重特異性ＧＰＣ３ｘＣＤ２８抗体およびＧＰＣ３ｘＣＤ３抗体ならびにそれらの組み合わせ | |
| IL312060A (en) | Bispecific CD16A binders | |
| RU2024139604A (ru) | Антитела к bcma |